You are here: Home \ Corporate \ Management

Joel Jessee, Chief Executive Officer and Chief Scientific Officer
Joel has been in product development for life science reagents for over thirty years. Prior to founding MTI, Joel was Vice President of R&D at Life Technologies/Invitrogen and at Atto Biosciences. He spent twenty years at LTI where he developed and introduced some of the most well recognized products for transformation, transfection and gene expression. He received a Masters degree in biology from Virginia Tech.  Joel is an inventor or co-inventor on numerous patents.

Gulilat Gebeyehu, Executive Vice President and Director of R&D.
Prior to joining MTI in the summer of 2002, Gulilat was Director of research at Life Technologies/Invitrogen where he worked for 20 years.  While at Life Technologies, he set up an organic chemistry laboratory and led a group of chemists that developed non-radioactive nucleic acid detection products including, the Ultrapure™ and transfection product lines. The chemistry group was also responsible for developing reagents and techniques for fast and high throughput oligonucleotide synthesis. He was lead chemist of the team of scientists that developed successful transfection reagents such as Lipofectin™ and the LipofectAmine™ family of products. Gulilat received his training at Brandeis University (BA) and New York University (PhD in Organic Chemistry), and he was a visiting fellow at the National Cancer Institute 1981-1983.

Dan Komarek, Chief Operating Officer
Dan has over twenty years of business, technical and operational experience with start-up biotech, life science companies and the government. Prior to working at MTI, he consulted with biotech companies in the US and Europe to help develop and commercialize their proprietary technologies. Prior to starting his own consulting business, he spent six years at BD Biosciences (formaly Atto Biosciences) as the Director of Business Development of the BioImaging division. There he focused on product development of instrumentation and software for the high content screening market. Prior to joining BD, he was Senior Manager of the Gene Discovery Services program at Life Technologies/Invitrogen where he oversaw the development and management of a new contract service program. He has also held management and technical positions at Bioreliance, Oncologix and USDA-ARS. He has a Biochemistry degree from University of Maryland.

Jonathan Aurbach, President and CSO GlobalStem
Jonathan is founder and President of Globalstem which he established in 2003. Prior to this he worked for ATCC where he established a new stem cell program. He was a post doctoral fellow at NIH, NINDS Laboratory of Molecular Biology from 1997-2001. He received his BS degree from Northwestern University in neurobiology, a M.Sc. in Neurobiochemistry from Tel Aviv University and a Ph.D. in Neurobiology from the Weizmann Institute of Science. Jonathan has over 20 research papers and book chapters in stem cell and neuroscience publications.

Ultrapure™, Lipofectin™ and Lipofectamine™ are trademarks of Life Technologies/Invitrogen Corporation.

• Management
• About Us